Conference Reports for NATAP

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention July 19th-22nd 2009 Capetown, South Africa Back

IAS: darunavir & etravirine studies       5th IAS: African-American Women Need Services is Highlighted in: GRACE (Gender, Race And Clinical Experience): 48-Week Results of Darunavir/r-based Therapy in the Largest Trial in North America to Focus on Treatment-experienced Women - (07/21/09) rather than enrolling African-Americans in studies this important study highlights again that services are needed for African-Americans, particularly women.   5th IAS: 48 week lipid- and glucose-related safety profile of darunavir/ritonavir in treatment-experienced, paediatric patients in DELPHI - (07/31/09)   5th IAS: Management of Treatment-Experienced Patients - written by Rafael E. Campo, MD Professor of Clinical Medicine Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine Miami, Florida (07/31/09)   5th IAS: ARTEMIS: Week 96 safety and efficacy of darunavir/r by gender, age and race - (07/29/09)   5th IAS: Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)   5th IAS: Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results - (07/29/09)   5th IAS: Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)   5th IAS: Efficacy and Safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial - (07/29/09)